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Abstract
Background: The regulation and function of mammalian RNAs has been increasingly appreciated to operate via
RNA-protein interactions. With the recent discovery of thousands of novel human RNA molecules by
high-throughput RNA sequencing, efficient methods to uncover RNA-protein interactions are urgently required.
Existing methods to study proteins associated with a given RNA are laborious and require substantial amounts of
cell-derived starting material. To overcome these limitations, we have developed a rapid and large-scale approach
to characterize binding of in vitro transcribed labeled RNA to ~9,400 human recombinant proteins spotted on
protein microarrays.
Results: We have optimized methodology to probe human protein microarrays with full-length RNA molecules and
have identified 137 RNA-protein interactions specific for 10 coding and non-coding RNAs. Those proteins showed
strong enrichment for common human RNA binding domains such as RRM, RBD, as well as K homology and CCCH
type zinc finger motifs. Previously unknown RNA-protein interactions were discovered using this technique, and
these interactions were biochemically verified between TP53 mRNA and Staufen1 protein as well as between HRAS
mRNA and CNBP protein. Functional characterization of the interaction between Staufen 1 protein and TP53 mRNA
revealed a novel role for Staufen 1 in preserving TP53 RNA stability.
Conclusions: Our approach demonstrates a scalable methodology, allowing rapid and efficient identification of
novel human RNA-protein interactions using RNA hybridization to human protein microarrays. Biochemical
validation of newly identified interactions between TP53-Stau1 and HRAS-CNBP using reciprocal pull-down
experiments, both in vitro and in vivo, demonstrates the utility of this approach to study uncharacterized
RNA-protein interactions.
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Background
Functional roles for both coding and non-coding RNA
molecules have been increasingly appreciated in a variety of
biologic processes, including gene regulation, molecular
trafficking, and protein translation [1-4]. For example,
mRNAs of coding genes are increasingly recognized as tar-
gets of translational regulation by a variety of mechanisms
[5,6]. Additionally, thousands of long non-coding RNAs
have recently been identified [7-9] and a growing number
of these are being assigned discrete biologic functions
[10-13]. Strategies to identify multiple RNAs binding an
individual protein of interest have advanced further than
those designed to identify multiple proteins binding a
given RNA. Examples of the former include immunopre-
cipitation followed by microarray hybridization (RIP-Chip)
or sequencing (RIP-Seq) [8,14,15]. Available approaches to
accomplish the latter include RNA pull-downs in which
proteins bound to biotin-labeled RNA are isolated and
analyzed by techniques including mass spectrometry [16].
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to an individual RNA of interest will allow characterization
of the molecular mechanisms of action and the functional
role of specific RNAs in human disease.
The recent use of protein microarrays in yeast [17,18]
suggests a similar approach may be of utility in the more
complex human setting. Commercially available human
protein microarrays were designed for detection of
protein-protein interactions using protein or small
molecule probes. As protein microarrays permit high
throughput screening for intermolecular interactions,
they may also provide an alternative approach to study
human protein-RNA interactions, an application in
which they have not yet been reported. Here, we demon-
strate a high-throughput methodology allowing rapid
identification of the proteins binding to a given human
RNA molecule using a protein microarray containing
~9,400 human recombinant proteins spotted in dupli-
cate. As a result of this approach we identify previously
uncharacterized interactions between HRAS RNA and
CNBP protein, as well as human Stau1 and TP53 RNA
and show that Stau1 influences TP53 RNA stability in
the context of transcriptional blockade.
Results and discussion
To define RNA-protein interactions, we utilized sense
and antisense strands for 10 RNA transcripts represent-
ing protein coding RNAs TP53, HRAS, MYC, BCL2 and
non-coding RNAs PWRN1, SOX2OT, OCC1, IGF2RNC,
lncRBM26 and DLEU1. The schematic diagram of the
workflow used in this work is presented on Figure 1A
and a detailed protocol of probe preparation, labeling
and hybridization conditions are included in experi-
mental procedures section as well as in Additional file 1:
Figure S1 and Additional file 2: Table S1. Briefly, the
aforementioned RNAs were in vitro transcribed, labeled
with Cy5 and independently probed on human pro-
tein microarrays. The labeling process was optimized in
order to achieve ~ 3 pmol dye per μgR N Aw i t ha n
average efficacy of 1 dye molecule for approximately
every 850 bp RNA (Additional file 2: Table S1) to min-
imally influence RNA native structure while yielding
signal intensities that are readily visualized (Figure 1B).
In order to determine the reproducibility of RNA-
protein interactions observed with this technology, we
performed technical replicates of HRAS sense RNA in-
cubation to the microarray. Comparison of the ratio of
signal intensity above background of every spotted pro-
tein between the two independent replicates demon-
strated suitable results with a Pearson correlation of
r
2=0.869 (Figure 1C). We next analyzed the distribution
of the signal within each array to establish filtering cri-
terion for RNA-protein interaction significance. A
representative distribution of signal intensities for all
proteins from the TP53 sense RNA array displaying
deviations from the global mean (Z-Scores) is shown on
Figure 1D. It is notable that there is a large fraction of
proteins that display a signal intensity ratio over back-
ground of 1, suggesting the absence of a global non-
specific fluorescence. We selected filters allowing identi-
fication of the significant RNA-protein binding events
based on a Z-Score ≥ 3.0 and a minimum signal above
background of 2.5 fold. Gene lists of all significant hits
from all hybridized RNAs in this study were generated
(Additional file 3: Table S2), and overlaps of hits from
the two technical replicates of HRAS sense RNA probed
to protein array resulted in a significance of p < 10
-72
(Figure 1E).
Next, functional characterization of the proteins that
significantly bound to RNAs used in this study was per-
formed. Of the 9125 spotted proteins – not including
spotted protein controls – only 196 proteins significantly
bound to at least 1 of the 20 RNAs. These 196 RNA
binding proteins were strongly enriched for protein fam-
ily domains compiled in the Pfam database that have
previously been identified in RNA binding, including the
RNA recognition motif, RNA binding domain, zinc fin-
ger and K homology domains (Figure 2A). Gene Onto-
logy (GO) terms associated with RNA binding, RNA
processing, and RNA splicing among others were strongly
enriched (Figure 2B). Taken together, these findings de-
monstrate the selectivity of this technique to detect RNA-
protein interactions.
We selected a subset of these proteins that most fre-
quently bound RNAs (≥75% of all RNAs used) for further
domain analysis (Table 1). Interestingly, while 23 out of 28
of these “common RNA binding proteins” contain motifs
or domains previously characterized for RNA binding cap-
acity, several proteins such as UNG, KCNAB1, STK40,
PAGE1 and NUDT16L1 contain no well-characterized
RNA interaction domains despite repeated significant
RNA-protein binding events observed in at least 15 out of
20 RNA incubations to the protein array (Table 1). Among
these proteins, NUDT16L1 contains no defined domain at
all and PAGE1 has no known function except its specific
expression in variety tumors. In addition, a comparison of
the 28 common RNA binding proteins to those identified
by recent PAR-CL and PAR-CLIP-seq studies [19,20]
demonstrates that 21/28 and 18/28 of these proteins, re-
spectively, demonstrate RNA binding ability including
NUDT16L1.
RNA application to human protein microarrays there-
fore identified a set of human proteins with a broad cap-
acity for binding to multiple RNAs that contain known
RNA binding motifs as well as identified a number of
new proteins for future study that contain no canonical
motifs and no previously known RNA binding capacity.
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interactions, we selected proteins that significantly bound
sense, but not antisense RNAs, although some biologically
relevant interactions may take place with both sense and
antisense transcripts from a given locus. This analysis
resulted in 137 interactions, revealing a substantial range
of protein binding between individual mRNAs and non-
coding RNAs and identified specific interactions for fur-
ther study (Figure 2C).
To perform biochemical validation of our findings we
selected 2 of these newly identified interactions and
studied RNA-protein binding using reciprocal pull-down
experiments. First, Staufen1 (Stau1) was identified as a
protein-binding target of TP53 mRNA using protein
microarrays with signal over background 3.19-fold, Z-
score 4.24 (Additional file 3: Table S2). TP53 mRNA,
but not its antisense or any other RNA transcripts, dis-
played a specific interaction with the duplicate Stau1
protein spots (Figure 2C and 2D). Antibody to an HA
epitope-tagged Stau1 protein immunoprecipitated TP53
mRNA but not control RNAs in both in vitro and
in vivo RNA-protein pull-down assays (Figure 3A and 3B).
Conversely, using reciprocal RNA pull-down experiments,
biotin-labeled TP53 mRNA – but not biotin-labeled con-
trols – pulled down Stau1 protein (Figure 3C). Therefore,
two-way pull-down experiments confirmed the novel
TP53 mRNA-Stau1 protein interaction identified using
human protein arrays.
A second interaction validation was undertaken for
the RING-type CCHC-zinc finger, nucleic acid binding
protein (CNBP), which bound HRAS mRNA on the pro-
tein microarray with signal over background 3.62-fold,
Z-score 3.82 (Figure 2C, Additional file 3: Table S2 and
Additional file 4: Figure S2A). The biotin-labeled HRAS
mRNA, but not biotin-labeled controls, pulled down
CNBP protein (Additional file 4: Figure S2B). Moreover,
in the complementary pull-down experiments, antibo-
dy to HA epitope-tagged CNBP protein immunopre-
cipitated HRAS mRNA but not control RNAs both
in vitro (Additional file 4: Figure S2C), as well as in vivo
(Additional file 4: Figure S2D). These two-way studies of
two independent, novel targets support the validity of
RNA-protein interactions detected by RNA incubation to
the human protein microarray and further verifies the
capability of this method.
To further address significance of TP53 association
with Stau1 protein, several deletion mutants spanning
the UTRs of TP53 RNA were generated and used for
Stau1-HA protein pull-down (Figure 3D and 3E). Al-
though we could not identify any known Stau1 binding
sequence motifs [21] within the TP53 UTR, pull-down
experiments indicated that Stau1 protein preferentially
binds within a 256 bp sequence of the TP53 3
0UTR.
Moreover, repeated incubation of the TP53 open reading
frame to the protein array demonstrated absence of
binding signal to Stau1 duplicate spots (Additional file 4:
Figure S2E), while the full-length TP53 RNA showed
binding (Figure 2D), confirming the finding that Stau1
protein binding takes place within the TP53 3
0UTR.
Stau1 protein is known to be involved in several cellu-
lar functions including RNA decay (in combination with
UPF1) [22], RNA transport [23], RNA translation [24]
and modulation of stress response [25] via shuffling bet-
ween polysomes and stress granules. To explore con-
sequences of Stau1 binding to TP53 RNA we studied
TP53 RNA stability in STAU1 and UPF1 deficient cells.
Unexpectedly, we found that although UPF1 depletion
did not affect overall TP53 RNA levels (Additional file 4:
Figure S2F), STAU1 knock down caused reduction in
TP53 RNA half-life in actinomycin D treated primary
fibroblast cells, under conditions known to halt synthesis
of newly formed RNA molecules (Figure 3F). Moreover,
after introduction of the full-length TP53 and TP53-ORF
(lacking 3
0UTR and Stau1 protein binding site) in TP53
negative H1299 cells, STAU1 knock down caused reduc-
tion in the full-length TP53 RNA half-life but did not
affect TP53-ORF RNA after actinomycin D treatment
(Figure 3G). These initial findings indicate that Stau1
protein binding to TP53 RNA may play a role in pre-
serving TP53 RNA levels in the setting of a transcrip-
tional blockade.
The diversity of naturally occurring RNA-protein
interactions is only beginning to be appreciated and
RNA hybridization to human protein microarrays may
be a useful complement to current platforms in a num-
ber of ways. For example, this approach can be used to
(See figure on previous page.)
Figure 1 RNA incubation on human protein microarrays. (A) Experimental and analytical workflow. (B) RNA incubation signal on protein
microarray. Sense [red] and antisense [green] strand signal is shown for the SOX2OT non-coding RNA, with pseudocolor images of independently
probed arrays. Panels at left show the entire microarray spotted with ~9400 recombinant human proteins; the middle panel is an enlarged 484
protein spot sub-array and the right panels represent an enlargement of the binding signal demonstrating strand-specific binding to the RBPMS
protein [GenBank:BC003608] [all proteins spotted in duplicate; sub-array positive controls boxed in red]. (C) Scatter plot of signal intensity above
background for all proteins between two independent replicates of the HRAS sense mRNA. Pearson correlation r
2 value is shown at right. (D) RNA
binding signal intensity over background distribution for TP53 sense RNA to the all proteins. Mean and Z-Scores (standard deviations from mean)
are depicted in blue with selected fold change cutoff of 2.5 in red. A Z-Score ≥ 3 and signal intensity over background ≥ 2.5 are used to select
significant RNA-protein binding event. (E) Venn diagram of significant hits from two independent HRAS mRNA incubations to protein array from
(C), (p value, Fisher’s exact test).
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Figure 2 RNA binding proteins identified by incubation of labeled RNAs to human protein microarrays. (A) Pfam protein family domains
and motifs present in proteins bound to at least 1 RNA (B) Gene ontology (GO) terms present in the same population of RNA binding proteins
from (A). (C) Binary heat map representation of the RNA binding capacity to protein microarrays. Human coding and non-coding RNAs used in
incubation to the microarrays are displayed in columns. The 137 out of 9400 total proteins bound by sense but not antisense strand RNA samples
with ≥ 2.5-fold above background intensity and Z-Score ≥ 3 are displayed in rows. Stau1 and CNBP protein localization indicated with arrows.
(D) Image and quantification of human protein microarray showing selective binding signal of TP53 mRNA sense strand to duplicate Stau1
protein spots. The binding signal is shown with respect to adjacent proteins spotted in the same sub-array.
Table 1 Common RNA binding proteins and their conserved domains
Gene name Protein description (NCBI Protein) Conserved % of all
RNAs
significantly
bound
Domains
CIRBP Cold-inducible RNA-binding protein RRM 90%
SFRS13A FUSIP1 protein RRM 85%
CPEB4 CPEB4 protein RRM 85%
PTBP2 Polypyrimidine tract binding protein 2 RRM 80%
TIA1 TIA1 protein RRM 80%
TIAL1 TIAL1 protein RRM 75%
RBMS3 RNA-binding motif, single-stranded-interacting protein 3 RRM 95%
PTBP1 Polypyrimidine tract-binding protein 1 isoform c RRM 95%
PCBP2 Poly(rC)-binding protein 2 isoform b PCBP_like_KH, KH-I 100%
NOVA1 RNA-binding protein Nova-1 isoform 1 PCBP_like_KH,KH-I 90%
PCBP2 Poly(rC)-binding protein 2 isoform a PCBP_like_KH, KH-I 90%
PCBP1 Poly(rC) binding protein 1 PCBP_like_KH, KH-I 80%
QKI Protein quaking isoform HQK-6 SF1_like-KH 95%
QKI Protein quaking isoform HQK-7B SF1_like-KH 90%
QKI Protein quaking isoform HQK-5 SF1_like-KH 80%
KHDRBS2 KH domain-containing,RNA-binding protein 2 SF1_like-KH 85%
KHDRBS3 KHDRBS3 protein SF1_like-KH 75%
ZNF385b ZNF385B protein Zf-met 90%
MBNL1 Muscleblind-like protein 1 isoform a Zf-CCCH 75%
ZC3H10 Zinc finger CCCH domain-containing protein 10 Zf-CCCH 95%
TARBP2 RISC-loading complex subunit TARBP2 isoform b DSRM 95%
TARBP2 RISC-loading complex subunit TARBP2 isoform a DSRM 100%
RPA1 Replication protein A 70 kDa DNA-binding subunit RPA1N,RPA1_DBD_C 75%
UNG Uracil-DNA glycosylase isoform UNG2 UDG_F1 95%
KCNAB1 Voltage-gated potassium channel subunit beta-1 isoform 1 Aldo_ket_red, Tas 95%
STK40 Serine/threonine-protein kinase 40 PKc_like 75%
PAGE1 G antigen family B member 1 GAGE 75%
NUDT16L1 Protein syndesmos isoform 1 None 75%
RRM – RNA recognition motif, PCBP_like_KH – Poly r(C) binding protein like K homology domain, KH – K homology RNA binding domain, KH-I – K homology RNA binding
domain type I, SF1_like-KH – Splicing factor K homology RNA binding domain, Zf-CCCH – Zinc-finger of CCCH [C-x8-C-x5-Cx3-H] type, DSRM – Double-stranded RNA
binding motif, Aldo_ket_red – Aldo-keto reductase, Tas – predicted oxidoreductase, UDG_F1 – family 1 of Uracil-DNA glycosylase, RPA1N – replication protein A
N-terminal OB fold domain, RPA1_DBD_C – replication protein ssDNA binding domain DBD-C, PKc_like – Protein Kinase C family, GAGE – GAGE protein family.
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coding RNAs by understanding the proteins to which
they bind. The ability to test the binding capability of
any coding or non-coding RNA to thousands of proteins
simultaneously will significantly improve the pace of
mechanistic analyses of RNAs. In this regard, it may
provide a complement to biotin-labeled RNA pull-
down/mass spectrometry-based approaches, which have
proven successful in identifying RNA binding proteins
[8] but require substantial amounts of cell-derived start-
ing material and are laborious and time-consuming.
RNA hybridization to human protein microarrays, in
contrast, requires minimal amounts of RNA and can be
completed in less than one day. However, the use of en-
tirely recombinant components for this method pre-
cludes the detection of RNA-protein interactions that 1)
require intact protein complexes, 2) require post-
translational modifications of protein, and 3) take place
with proteins not spotted on the array.
RNA hybridization to human protein microarrays may
also help to understand proteins that bind and regulate
the stability, localization, or translational control of pro-
tein coding transcripts. In this regard, Stau1, a known
RNA-binding protein implicated in both RNA stability
and localization [22-24], was shown in this work to
regulate TP53 in an as yet previously uncharacterized
way. Similarly, the binding of CNBP to HRAS RNA may
also modulate Ras function. Moreover, it is intriguing to
note that human genetic disorders arising from muta-
tions in both CNBP (Myotonic Dystrophy [26]) and
HRAS (Costello Syndrome [27]), while displaying dis-
tinctive features, both display profound abnormalities in
muscle tissue. Similarly, we observed the Prader-Willi
Syndrome associated long non-coding RNA, PWRN1, to
bind the SPATA17 protein, which has been linked to
apoptosis of spermatogenic cells [28]. As hypogonadism
is a known symptom of Prader Willi Syndrome, this ob-
servation may provide a functional link between this
non-coding RNA and its associated human disease. In-
cubation of specific human RNAs of interest to human
protein microarrays may therefore help characterize
mechanisms of RNA function and may also stimulate
efforts to identify potential uncharacterized links in the
pathogenesis of human disease.
Conclusions
Here we describe a refined methodology for rapid and
large-scale identification of novel human RNA-protein
interactions. RNA hybridization to human protein mi-
croarrays described here offers several attractive features.
First, the reagents required are readily available, consis-
ting of minimal amounts of in vitro transcribed RNA
and standardized, commercially available protein micro-
arrays. Second, RNA hybridization to human protein mi-
croarrays does not require large-scale cell culture for
protein isolation and mass spectrometry, and hence it is
far less laborious than current RNA chromatography
techniques. Third, this technique is rapid, taking less than
a day to complete. Biochemical verification of newly iden-
tified RNA-protein interactions using this technique via
reciprocal and independent pull-down experiments per-
formed here moreover suggests that there are many un-
discovered human-RNA protein interactions and that this
approach may be helpful in identifying them.
Methods
Plasmid vectors and expression constructs
Plasmid vectors containing full-length transcribed sequen-
ces for coding and non-coding RNAs were obtained from
Open Biosystems (Thermo Scientific) and are described in
detail in Additional file 2: Table S1. All plasmids except
pDNRLIB contain T7, T3 or SP6 promoters for sequencing
and in vitro RNA production. pDNRLIB-DLEU1 plasmid
contains the T7 promoter for sense RNA transcription.
To produce antisense DLEU1 RNA, a 945 bp DLEU1 se-
quence was recloned from pDNRLIB into pSPORT1 vector
using EcoRI and XhoI sites and pSPORT1-DLEU1 was
used for antisense RNA production via SP6 promoter. For
in vivo RNA production we constructed a small eukaryotic
expression vector pSPARTA containing the human PGK
promoter controlling expression of the transcribed se-
quence and puromycin resistance gene for selection in
both prokaryotes and eukaryotes, which is under control of
the synthetic bacterial EM7 and viral CMV promoter
(See figure on previous page.)
Figure 3 Confirmation of RNA-protein binding on microarrays with reciprocal pull-down assays for Staufen1 with TP53 mRNA.
(A) Stau1-HA protein pulls down TP53 mRNA in vitro after immunoprecipitation with HA Mab; immunoblots to HA-tagged Stau1 verifying Stau1
precipitation are shown on the left panel. (B) Stau1-HA protein pulls down TP53 mRNA in vivo, but not HRAS and GAPDH control RNAs after
immunoprecipitation with HA Mab; immunoblots to HA-tagged Stau1 verifying Stau1 precipitation from cell extracts are shown on the left panel.
(C) Pull-down of biotin labeled human TP53 mRNA in vitro, but not HRAS or LacZ mRNA precipitates associated Stau1-HA protein; densitometry
quantification of the immunoblots shown on the right panel. (D) Schematic diagram of TP53 mRNA constructs. Numbering corresponds to the
first nucleotide following the termination codon, defined as 1. Signs (“+” and “–“) represent ability or failure of Stau1-HA to bind TP53 RNA
constructs. (E) Pull-down of biotin labeled human TP53 mRNA deletion constructs in vitro, followed by western blot analysis of the associated
Stau1-HA protein; densitometry quantification of the immunoblots shown on the right panel. (F) TP53 RNA decay in Primary Fibroblasts after
actinomycin D treatment. (G) Comparison of full-length TP53 and TP53-ORF (lacking Staufen 1 interaction domain) RNA decay in TP53 negative
H1299 cells after actinomycin D treatment.
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[GenBank:NM_000546] was recloned from the original
pSPORT1-TP53 vector as a SalI-ClaI fragment of 2560 bp
into SalI-EcoRV of pSPARTA. The TP53 deletion mutants
containing 5
0UTR and 197bp of 3
0UTR were constructed
by flanking TP53 fragments with either HindIII-XhoI or
EcoRI-XhoI and cloning into pcDNA3 expression vector to
generate pcDNA3-TP53-ORF-5
0UTR and pcDNA3-TP53-
ORF-3
0UTR197. The constructs containing TP53-ORF,
TP53-ORF-3
0UTR (full-length) and TP53-ORF-3
0UTR453
fragments were generated by direct amplification and TA
cloning into pcDNA3.1TOPO expression vector. Num-
bering for 3
0UTR deletion constructs corresponds to the
first nucleotide following the termination codon, de-
fined as 1. The full-length TP53 expression construct
used for transfection of H1299 cells was constructed by
recloning HindIII-NotI fragment from pSTARTA-TP53
into pcDNA3 in order to take advantage of the neomy-
cin selection cassette in H1299 cells.
Human V-Ha-Ras homolog [GenBank:BC006499] was
recloned from pOTB7 vector as 1146 bp EcoRI-XhoI frag-
ment into EcoRV-XhoI of pSPARTA. Both plasmids
pSPARTA-TP53 and pSPARTA-HRAS were used in pull-
down experiments in vivo as described below. In vivo ex-
pression constructs for Stau1 and CNBP were generated
using pcDNA3.1Hygro plasmid (Invitrogen). The ORFs of
Stau1 and CNBP were flanked with 3x hemagglutinin
(HA) tag at 3
0 end for Stau1 and 5
0 end for CNBP using
PCR techniques and the following primers:
STAUF, 5
0TTTTAAGCTTACCATGTCTCAAGTTCAAG
TGCAAGTT.
STAUHAR,
5
0TTTTCTCGAGTCAGGCGTAATCGGGCACGTCGTA
GGGATAGCTTCCTGCATAATCAGGGACGTCATAGG
GATAGCCAGCATAGTCAGGCACATCGTATGGGTAG
CACCTCCCACACACAGACA.
CNBPHAF, 5
0TTTTAAGCTTACCATGTACCCATACGA
TGTGCCTGACTATGCTGGCTATCCCTATGACGTCC
CTGATTATGCAGGAAGCTATCCCTACGACGTGCCC
GATTACGCCAGCAGCAATGAGTGCTTC AAG.
CNBPR, 5
0TTTTCTCGAGTTAGGCTGTAGCCTCAAT
TGTG.
The epitope tagged fragments were cloned in HindIII-
XhoI sites of pcDNA3.1Hygro and the final constructs
pcDNA3.1Hygro-STAU1-HA and pcDNA3.1Hygro-HA-
CNBP were used for RNA pull-down studies.
In vitro RNA production and labeling
For the 10 RNA expression sequences used in this study,
RNAs for coding (TP53, MYC, HRAS, BCL2) and non-
coding (OCC1, IGF2RNC, PWRN1, DLEU1, lncRBM26,
SOX2OT) genes were in vitro transcribed in both sense
and antisense directions using T7, T3 or SP6 promoters
(Additional file 2: Table S1). First, plasmid DNA was
digested with enzymes immediately flanking the tran-
scribed sequence and 4 μg of linear DNA was used for
in vitro transcription in 50 μl total volume consisting of:
1x Transcription buffer (Promega), 10 mM DTT (Pro-
mega), 1 mM NTP (Invitrogen), 40 units RNAseOUT
(Invitrogen) and 60 units RNA polymerases (T7, T3 or
SP6). The reaction was carried out at 37°C for 4 hours
after which DNA was digested by addition of 2 units
DNAse I at 37°C for 15 minutes. Next, RNA was
phenol-chloroform extracted and after ethanol precipita-
tion measured using NanoDrop 1000 spectrophotometer
(Thermo Scientific) and visualized using denaturing agar-
ose gel-electrophoreses (Additional file 1: Figure S1C).
RNA labeling for microarray incubations was per-
formed using Label IT μArray Cy5 labeling kit (Mirus).
We first carefully optimized the labeling procedure in
order to achieve between 1 to 3 Cy5 dyes covalently
attached to RNAs used. This was accomplished via the
following modifications from the original manufacturers
protocol: the total reaction volume was kept at 25 μl, the
ratio of RNA:Label IT Cy5 reagent at 10:1 (w:v) and re-
action time not more then 30 minutes at 37°C. Briefly,
5 μg RNA in water was mixed with 5 μl Label IT Cy5,
diluted 1 to 10 in water to obtain a final volume of 25 μl
and incubated 30 minutes at 37°C. The reaction was
stopped by addition 2.5 μl of 10x STOP buffer (Mirus).
The volume was increased to 100 μl with water, supple-
mented with glycogen (Invitrogen) to final concentration
of 0.2 μg/μl, mixed and RNA ethanol precipitated in the
presence of 0.5 M NaCl at −20°C for at least 1 hour.
The labeled RNA was extensively washed in 70% etha-
nol, dried and resuspended in 16 μl water. RNA labeling
density was evaluated using NanoDrop 1000 spectropho-
tometer (Thermo Scientific) and visualized using de-
naturing agarose gel-electrophoreses.
The efficacy of Cy5 dye incorporation was calculated
as dye density (pmol Dye: μg RNA) and RNA Base:Dye
ratio. To calculate the dye density following formula
was used:
pmol Dye : μg RNA =Adye/edye(pmol)/MRNA,(μg),
where
Adye – Cy5 absorbance at Imax (excitation wavelength)
649 nm,
edye – Cy5 dye extinction coefficient 250 000 M
-1 cm
-1,
MRNA – RNA amount (μg).
Base:Dye ration was calculated using following formula:
(Abasexe dye)/(Adyexe base), where
Abase =A 260 – (Adye x C.F.260) – RNA base absorbance,
A260 – absorbance of the nucleic acid, C.F.260 –
correction factor for Cy5=0.05,
ebase – RNA extinction coefficient 8250 M
-1 cm
-1
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for each 20 sense and antisense RNAs used in this work
is presented in Additional file 2: Table S1, with an RNA
labeling efficacy required of 1 Cy5 dye per 700 – 1200
bp RNA.
RNA labeling with Biotin-16-UTP was performed dur-
ing in vitro transcription. First, plasmid DNA containing
transcribed sequence was digested with enzymes imme-
diately flanking the insert and 4 μg of linear DNA was
used for RNA biotinilation reaction in 50 μl total volume
consist of: 1x Transcription buffer (Promega), 1 mM
ATP, 1mM CTP, 1mM GTP, 0.95 mM UTP, 0.05 mM
Biotin-16-UTP (Roche), 10 mM DTT (Promega), 40 units
RNAseOUT (Invitrogen) and 60 units RNA polymerases
(T7, T3 or SP6). The reaction was carried out at 37°C
for 4 hours after which DNA was digested by addition
of 2 units DNAse I at 37°C for 15 minutes. Next, RNA
was phenol chloroform extracted, and after ethanol pre-
cipitation, characterized using NanoDrop 1000 spectro-
photometer (Thermo Scientific) and visualized using
denaturing agarose gel-electrophoreses (Additional file 1:
Figure S1D).
ProtoArray processing and analysis
For RNA incubation, ProtoArray Human Protein Micro-
array v5.0 (Invitrogen, cat# PAH052520) was used. Prior to
incubation, each microarray was equilibrated first to
4°C overnight and then to 25°C for at least for 15 minutes.
The microarray slide was assembled in a Gentel SIMplex
16 Multi-Array System device (Gentel biosciences, cat# 4–
1007) with custom modifications including a modified bot-
tom gasket and top spacers (Additional file 1: Figure S1A).
The bottom gasket was cut out from silicone slab as a rect-
angular seal with the following dimensions in mm: outer
65L × 25W × 4H, inner 59L × 20W × 4H. Top spacers
were cut out from a polycarbonate piece as a rectangular
shape with the following dimensions in mm: Upper spacer
5L × 22W × 1H, lower spacer 12L × 22W × 1H. First, the
microarray slide was placed inside a Gentel SIMplex 16
Multi-Array device bottom holder piece, next the silicone
gasket was carefully placed on the top of the slide and the
device top piece held in place with tightening screws. The
slide surface was blocked in 0.7 mL blocking buffer BL:
40 mM Tris–HCl (pH 8.0), 1% BSA (w/v) (globulin free,
Sigma, cat# A7638), 100 μg/ml Yeast tRNA, 20 μg/mL hep-
arin and 1 mM DTT for 1 hour at room T°C with gentle
agitation. After completion of the blocking step, 10 pmol
Cy5 labeled RNA was added to 0.7 mL binding buffer BB:
40 mM Tris–HCl (pH 8.0), 150 mM sodium chloride,
0.5 mM magnesium acetate, 10 μg/ml Yeast tRNA, 10 μg/
mL heparin, 1 mM DTT, 0.01% Igepal CA-630, 5% glycerol,
0.2 units/μl RNAseOUT. The blocking buffer was replaced
with binding buffer containing labeled RNA and microarray
slides incubated in the dark at 25°C for 1 hour with gentle
agitation. Following RNA incubation binding buffer was
r e m o v e da n dw a s h i n gs t e p sw e r ei m p l e m e n t e du s i n g3
times exchange of 0.75 mL WB buffer: 40 mM Tris–
HCl (pH 8.0), 150 mM sodium chloride, 0.5 mM mag-
nesium acetate, 10 μg/ml Yeast tRNA, 10 μg/mL hep-
arin, 1 mM DTT, 0.01% Igipal 40, 5% Glycerol, 0.2
units/μl RNAseOUT for at least 5 minutes each. Finally,
the microarray slide was washed in 0.75 mL washing buffer
WBF: 40 mM Tris–HCl (pH 8.0), 150 mM sodium chlor-
ide, 0.5 mM Magnesium acetate, 10 μg/ml Yeast tRNA,
10 μg/mL heparin, 1 mM DTT, at least 3 times for 5 min-
utes each. After the last wash, the WBF buffer was
removed partially in order to prevent the slide from drying
p r e m a t u r e l ya n ds l i d eh o l d e rd e v i c ed i s a s s e m b l e di m m e d i -
ately. The probed microarray slide was placed in ArrayIt
microarray high-speed centrifuge and the residual WBF
buffer removed via a 30 seconds of centrifugation. The dry
slide was scanned at 635 nm (Cy5) using a GenePix 4000B
Microarray scanner (Molecular Devices) immediately after
or at least within 2 hours of the completion of the incuba-
tion. All raw and processed data is publicly available at the
Gene Expression Omnibus under accession GSE34794
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=t-
tehdwscqcgckrg&acc=GSE34794). For the visualization
process, the array images from antisense RNA incuba-
tions were pseudocolored green and overlaid with the
sense RNA incubation. The intensity of the 635 nm wave-
length signal at each spotted protein location was de-
termined with GenePix Pro 6.1 software (Molecular
Devices). To quantify RNA-protein interactions, the in-
tensity of 635 nm signal (F635) was divided by the local
background intensity (B635) at each of the duplicate spots
for a given protein. Data was filtered based on signal
above the background for each of the duplicate feature to
be greater than 2.5 fold and Z-Score ≥ 3f r o mt h eg l o b a l
mean signal from all of the spotted proteins. In order to
select sense-specific protein interactions, the signal gener-
ated from antisense RNA incubations were calculated
based on 2.5 fold above the background and Z-Score ≥ 3.
Significant hits from the antisense were subtracted from
the significant hits in the sense RNA. Hierarchical cluster-
ing analysis was performed by Cluster 3.0 (Eisen Lab) and
visualized with TreeView. Gene Ontology analysis and
PFAM domain analysis of RNA binding proteins was per-
formed with DAVID [29] using as a background a uni-
verse of gene list of all proteins spotted on the microarray
and Benjamini-Hochberg correction of the p value. The
p value of the Venn diagram illustrating overlap of two
independent microarray incubations was calculated using
Fisher’s exact test.
RNA-protein complex pull-downs
RNA-protein complex pull-downs were performed in two
complementary directions: first, by immunoprecipitation
Siprashvili et al. BMC Genomics 2012, 13:633 Page 10 of 13
http://www.biomedcentral.com/1471-2164/13/633of target protein with following associated RNA detection
using qPCR technique. Second, by pulling-down biotin la-
beled RNA and detecting RNA associated protein via
western blot analyses.
In vitro protein IP with subsequent RNA detection
For in vitro protein RNA complex immunoprecipitation
both Stau1-HA and HA-CNBP proteins were in vitro
translated using rabbit reticulocyte lysate system (Pro-
mega) in accordance with manufacturer’s recommenda-
tions. The full-length human TP53 and HRAS mRNA
transcripts were in vitro transcribed as described in
above. Prior to RNA-protein complex formation, 20 μl
Protein G Dynabeads (Invitrogen) were saturated in
500 μl buffer IPB containing 40 mM Tris–HCl (pH 8.0),
150 mM sodium chloride, 0.5 mM Magnesium acetate,
20 μg/mL heparin, 1 mM DTT, 0.01% Igepal CA-630,
5% Glycerol, supplemented with 0.5% BSA, 100 μg/ml
Yeast tRNA and protease inhibitors complete mini
(Roch) and mixed with 2.5 μg anti-HA antibody (HA.11,
clone 16B12, Covance) for 1 hour with continuous agita-
tion at 25°C. 12.5 μl of in vitro translated protein was
mixed with 250 ng RNA in 500 μl buffer IPB supple-
mented with 0.2 units/μl RNAseOUT and incubated
1 hour at 25°C with gentle agitation. After one wash of
HA-bound protein G Dynabeads in IPB buffer protein-
RNA complex was added to the beads and incubated
for 1 hour at room T°C. As a control, pre-blocked pro-
tein G Dynabeads lacking HA antibody was added to
the same amount of protein-RNA complex and pro-
cessed identically to the sample tube. After completion
of the protein capture on Dynabeads, five separate
washes for ten minutes duration each were implemen-
ted using IPB buffer. Magnetic beads were resuspended
in 100 μl IPB and 10% removed for protein analysis via
western. The RNA from the residual mixture containing
protein-RNA complex was extracted with phenol-
chloroform then ethanol precipitated for resuspension
in 11.5 μl water in order to use for cDNA synthesis
with iScript cDNA Synthesis kit (Bio-Rad). After com-
pletion of the reverse transcription, DNA samples were
subjected to qPCR using Maxima SYBR Green qPCR
master mix (2x, Fermentas) and gene specific primers
sets:
TP53_F: 5
0CCAGCCAAAGAAGAAACCAC
TP53_R: 5
0TGAGTTCCAAGGCCTCATTC
HRAS_F: 5
0AGCAGATCAAACGGGTGAAG
HRAS_R: 5
0AGCCAGGTCACACTTGTTCC
The qPCR was performed on Stratagene Mx3000P
QPCR system (Agilent Technologies) and results were
analyzed with MxPro QPCR software v. 4.1.
In vivo protein IP with subsequent RNA detection
For in vivo protein-RNA complex pull-down experi-
ments 293T cells were transfected with expression vec-
tors pcDNA3.1Hygro-STAU1-HA, pSPARTA-TP53, and
pcDNA3.1Hygro-HA-CNBP pSPARTA-HRAS in 10 cm
plates using FuGENE 6 transfection reagent (Roche) in
accordance with the manufacturer’s instructions. Cells
were collected 48 hours post-transfection in 2 volumes
(v/v cell pallet) of Buffer A: 10 mM Tris–HCl (pH 7.5),
0.1 mM EDTA, 1 mM DTT, 1 mM PMSF and protease
inhibitors complete mini (Roch) and incubated 15 min-
utes on 4°C. While cells were incubated on ice Protein G
Dynabeads were blocked and bound to HA mab as
described above using IPB buffer. After 15 minutes Igepal
CA-630 was added to cells to a final concentration of
0.01% and incubated additional 5 minutes at 4°C. Next,
cells were subjected to two freeze-thaw cycles by incubat-
ing on isopropanol/dry ice bath for 30 seconds and imme-
diately thawing at 37°C. After completion of the lyses,
1.5 μl of RNAseOUT (Invitrogen) was added for every
100 μl lysate and subjected to centrifugation at 1,000g for
5 minutes at 4°C. The cytosolic fraction was removed and
kept at 4°C, while to remaining pellet Buffer B was added
equal to the volume of original Buffer A supplemented
with 2.5 units of DNAse I for every 100 μl of original cell
pellet. Buffer B is composed of: 50 mM Tris–HCl (pH
7.5), 300 mM sodium chloride, 1 mM Magnesium acetate,
1 mM DTT, 10% Glycerol (v/v), 1 mM PMSF and protease
inhibitors complete mini (Roch). The lysate was passed
through 27 gauge needle, spun at 10,000g for 15 minutes
at 4°C and, after adding Igepal CA-630 to a final concen-
tration of 0.01%, combined with cytosolic fraction. Next,
the combined lysate was split in two parts and treated
with 20 μl Protein G Dynabeads with or without HA Mab
for 1 hour at room T°C. The magnetic beads were sub-
jected to at least 5 washing cycles using 500 μl IPB buffer
and, after collection in 100 μl buffer, 1/10 of the volume
was saved for protein analysis via western and from the
rest of the pull-down RNA extracted using TRIzol reagent
(Invitrogen) in accordance with the manufacturer’s
instructions. The RNA pallet was resuspended in 11.5 μl
in order to use for cDNA synthesis with iScript cDNA
Synthesis kit (Bio-Rad). After completion of the reverse
transcription, DNA samples were subjected to qPCR using
Maxima SYBR Green qPCR master mix (2x, Fermentas)
and gene specific primers sets indicated above together
with the control primers:
GAPDH_F: 5
0 GAAGAGAGAGACCCTCACTGCTG
GAPDH_R: 5
0ACTGTGAGGAGGGGAGATTCAGT
The qPCR was performed on Stratagene Mx3000P
QPCR system (Agilent Technologies) and results were
analyzed with MxPro QPCR software v. 4.1.
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For in vitro RNA pull-down TP53 full-length or deletion
mutants TP53-5
0UTR-ORF, TP53-ORF, TP53-ORF-
3
0UTR, TP53-ORF-3
0UTR453, TP53-ORF-3
0UTR197,
HRAS and LacZ mRNAs were labeled with biotin-16-
UTP as described above and Additional file 1: Figure
S1D. The control LacZ RNA was prepared as 1200 bp
fragment of the full-length LacZ via in vitro trans-
cription of the EcoRV digested pcDNA3.1HygroLacZ
(Invitrogen) with T7 polymerase in order to match the
average length of the sample RNAs used in this work.
The 5 μl in vitro translated Stau1-HA or HA-CNBP was
incubated with 1 μg biotin-16-UTP labeled TP53, HRAS,
or LacZ in IPB buffer for 30 minutes at 25°C. During
this reaction, 5 μl of MyOne Streptavidin T1 Dynabeads
(Invitrogen) were exchanged to IPB buffer using mag-
netic stand and added to protein RNA complex. The
mixture was incubated an additional 30 minutes and
subjected to five wash cycles of 5 minutes each using
500 μl IPB buffer. After the last wash, magnetic beads
were resuspended in 12 μl protein loading buffer, RNA
bound protein separated by SDS-PAGE and detected
with anti-HA Mab by western blot analysis.
RNA interference
siRNA oligonucleotide duplexes used in this work were
synthesized by Dharmacon (Thermo Scientific). 1x10
6
Pimary human Fibroblasts were electroporated with
1 nmol siRNA nucleotides using Amaxa Human Dermal
Fibroblast nucleofection kit (Lonza) following manufac-
turer’s instruction. The siRNA oligonucleotides were
used in this work:
siControl: 5
0 GUAGAUUCAUAUUGUAAGGUU
siUPF1 A: 5
0 CAGCGGAUCGUGUGAAGAA
siUPF1 C: 5
0 GCAGCCACAUUGUAAAUCA
The vectors for pGIPZ shRNA targeting Stau1 were de-
signed and purchases through Open Biosystems (Thermo
Scientific) catalog number RHS4531-NM_017452. The ef-
ficiency of knockdown was evaluated using following
oligonucleotides:
STAU_F: 5
0 ATGGTATCGGCAAGGATGTG
STAU_R:5
0 AGACATTGGTCCGTTTCCTG
UPF1_F: 5
0 ATATGCCTGCGGTACAAAGG
UPF1_R: 5
0 AGCTCAATGGCGATCTCATC
Tissue culture
All of the experimental procedures were carried out in
accordance with the local ethics commission. Primary
human dermal fibroblasts were isolated from neonatal
dermis and cultured at early passage in DMEM supple-
mented with 10% FBS. H1299 non-small cell lung
carcinoma cell line deficient for TP53 was cultured in
RMPI1640 supplemented with 10% FBS. H1299 cells
were transfected with pcDNA3-TP53 full-length or
pcDNA3.1TOPO-TP53-ORF constructs and selected for
3 to 5 days in 500 μg/mL neomycin. Next, cells were
transduced with pGIPZ-STAU1 virus and 36 hours later
selected with 1 μg/mL puromycin for 48 hours. For
RNA stability analysis, cells were plated 24hours before
at 40-50% confluence in 6 well plate and next day trea-
ted with 5 μg/mL actinomycin D (Sigma) for the indi-
cated times. Total RNA was prepared and gene
expression analyses as described above.
Additional files
Additional file 1: Figure S1. Protein microarray incubation device and
RNAs used for this work. (A) Modified Gentel SIMplex 16 device with
microarray slide and assembly components. Schematic diagram of the
custom-made silicone gasket and spacer with main dimensions indicated. (B)
Expression vector pSPARTA. hPGK - human phosphoglycerate kinase
promoter, SV40 polyA - simian virus 40 polyadenylation signal, bGlob polyA -
beta-globin polyadenylation signal, Puromycin - resistance gene, EM7 -
bacterial promoter, CMV Enh/Prom - cytomegalovirus enhancer promoter, Ori
- origin of replication. Unique site depicted in black. Polylinker sites are in red.
(C) Denaturing agarose gel electrophoresis of sense and antisense RNAs used
in this work. M - RiboRuler RNA ladder (bp): 6000, 4000, 3000, 2000, 1500, 1000,
500, 200. (D) Denaturing agarose gel electrophoresis of biotin-16-UTP labeled
RNAs TP53, HRAS, LacZ (1.2kb fragment of LacZ, experimental procedures). M -
RiboRuler RNA ladder (bp): 6000, 4000, 3000, 2000, 1500, 1000, 500, 200.
Additional file 2: Table S1. Expression constructs and promoters used
for the strand-specific RNA sequence production. The efficiency of RNA
labeling with Cy5 dye was calculated as described in Experimental
Procedures.
Additional file 3: Table S2. Significant RNA binding proteins for all
sense and antisense RNAs used in this work. Z-Score ≥ 3 and signal
intensity above background ≥ 2.5 was used to filter RNA-protein binding
events as described in the text.
Additional file 4: Figure S2. Confirmation of RNA-protein binding on
microarrays. The reciprocal pull-down assays for CNBP with HRAS mRNA.
(A) Quantitation images of human microarray showing selective binding
signal of HRAS mRNA sense strand to duplicate CNBP protein spots. The
incubation signal shown with respect to adjacent protein controls in the
same sub-array. (B) Pull-down of biotin labeled HRAS mRNA in vitro, but
not TP53 or LacZ precipitates associated HA-CNBP protein; densitometry
quantification of the immunoblots shown (right). (C) HA-CNBP protein
pulls down HRAS mRNA in vitro after immunoprecipitation with HA Mab;
immunoblots to HA-tagged CNBP verifying CNBP precipitation are shown
on the left panel. (D) HA-CNBP protein pulls down HRAS mRNA in vivo,
but not control TP53 and GAPDH mRNAs after immunoprecipitation with
HA Mab; immunoblots to HA-tagged CNBP verifying CNBP precipitation
from cell extracts are shown (left). (E) Incubation of TP53-ORF mRNA
sense strand lacking 50 and 30 UTR regions to human protein microarrays.
Panel at left shows the entire microarray spotted with ~9400
recombinant human proteins; the middle panels represent an
enlargement of the sub-array containing Stau1 and WIT1 proteins. Note
absence of the Stau1-TP53 mRNA association signal in comparison to
Figure 2D when full-length TP53 mRNA was probed. [all proteins spotted
in duplicate; Stau1 and WIT1 spots boxed in white; sub-array positive
controls boxed in red]. The quantification of the incubation results shown
on the right. (F) Contrary to STAU1 depletion, UPF1 KD has no affect on
TP53 RNA decay in Primary Fibroblasts.
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